ClinicalTrials.gg
CompletedNCT07940686SOOTHEUpdated Nov 17, 2026

Evaluating PNN Neurolysis for Migraine Relief

An interventional study of RhinAer in Migraine Headache, sponsored by Aerin Medical. Completed at 3 sites in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Aerin Medical · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Mar 2023, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 697 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
390th of 610
48 · median 78
Started
2023
with 38 others
No phase
204 of 697
32 open now
Registered
697th of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 390th largest by enrollment of the 610 interventional ones that give a count, is one of 39 that started in 2023, is one of 204 with no phase, and was the 697th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of posterior nasal nerve (PNN) neurolysis on the migraine symptoms of patients diagnosed with midfacial migraine headaches, including the frequency and intensity of migraine headache episodes.

03

Conditions studied

  • Migraine Headache

Browse trials for

04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented diagnosis or history of chronic rhinitis and/or vasomotor nasal symptoms (e.g., nasal congestion or rhinorrhea) during migraine episodes
  • recent CT scan to rule out sinusitis
  • response to a topical PNN block

    • 10 headaches per month with ≥5 having characteristics (e.g., unilaterality, pulsation, nausea/vomiting, photo/phonophobia) meeting criteria for migraine per the International Classification of Headache Disorders Classification of Headache Disorders, 3rd edition (ICHD-3).

Exclusion criteria

Exclusion Criteria:

  • limited access to the PNN treatment area,
  • active nasal or sinus infection, previous PNN ablation for chronic rhinitis
  • Lund-MacKay score of ≥6 on screening CT
  • Regular ongoing onabotulinumtoxinA treatment and/or treatment within the past 3 months
  • headaches attributable to a secondary cause.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    RhinAer

    Device: RhinAer

Interventions

  • DeviceRhinAer

    Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).

06

What researchers measure

Primary outcomes

  1. Change from baseline in Mid-facial Migraine Headache Days at 3 months

    Assess the treatment effect of PNN neurolysis using the RhinAer procedure for treatment of midfacial migraine headaches at 3 months. This primary outcome measures the change in mid-facial migraine headache days at baseline versus 3 months post-procedure.

    Time frame: Baseline (pre-procedure) and 3 months post-procedure

Secondary outcomes

  1. Change from baseline in Mid-facial Migraine Headache Days at 6 months

    Assess the treatment effect of PNN neurolysis using the RhinAer procedure for treatment of midfacial migraine headaches at 6 months. This secondary outcome measures the change in mid-facial migraine headache days at baseline versus 6 months post-procedure.

    Time frame: Baseline (pre-procedure) and 6 months post-procedure

07

Study locations

3 sites
  • Alabama ENT & Allergy
    Birmingham, Alabama 35242, United States
  • Piedmont ENT
    Atlanta, Georgia 30309, United States
  • Madison ENT
    New York, New York 10016, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2025, 32 months.

Of 49 industry-sponsored interventional studies with no phase under Migraine Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 32 months is above that.

Counting every sponsor, half of 358 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 17, 2026
StartActual
Mar 3, 2023
Primary completionActual
Nov 18, 2025
CompletionActual
Jun 2, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940686
Lead sponsor
Aerin Medical
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Mar 3, 2023
Primary completion
Nov 18, 2025
Completion
Jun 2, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion